Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KLRS
STRONG SELLKalaris Therapeutics, Inc. · Healthcare · United States · $89M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Kalaris Therapeutics, Inc. is an early-stage biotechnology company focused on discovering and developing novel therapeutic candidates for unmet medical needs. Its competitive position relies on proprietary intellectual property surrounding its drug candidates and scientific expertise in specific disease pathways. As a preclinical-stage firm, Kalaris Therapeutics represents a speculative healthcare venture, where valuation is driven by pipeline potential and scientific breakthroughs rather than current revenue.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 11.4M | — |
| EPS | -11.64 | -11.05 | -3.70 | -2.85 | — | -0.72 | -2.03 | -1.63 | — |
| Shares | 18.7M | 18.7M | 18.7M | 22.9M | +22.5% | 23.8M | — | — | — |
| Debt | 3.3M | — | 19.5M | 1.4M | -23.6% | 1.4M | — | — | — |
| Equity | -30.3M | -45.0M | -96.6M | 78.8M | — | — | — | — | — |
| Op CF | -9.8M | -14.1M | -20.7M | -38.4M | — | -42.5M | — | — | — |
| Inv CF | — | — | 0 | -19.7M | — | — | — | — | — |
| Fin CF | 12.8M | 14.2M | 19.1M | 155.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KLRS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KLRS | Kalaris Therapeutics, Inc.(you) | $89M | 9 | STRONG SELL |
| BMEA | Biomea Fusion, Inc. | $90M | 9 | STRONG SELL |
| HRTX | Heron Therapeutics, Inc. | $86M | 8 | STRONG SELL |
| TELO | Telomir Pharmaceuticals, Inc. | $79M | 9 | STRONG SELL |
| CGTX | Cognition Therapeutics, Inc. | $82M | 7 | STRONG SELL |
| IBIO | iBio, Inc. | $71M | 8 | STRONG SELL |
| ALDX | Aldeyra Therapeutics, Inc. | $92M | 4 | STRONG SELL |
| PLYX | Polaryx Therapeutics, Inc. | $102M | 6 | STRONG SELL |
| GANX | Gain Therapeutics, Inc. | $75M | 7 | STRONG SELL |
| ONCY | Oncolytics Biotech Inc. | $97M | 5 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%